Concepedia

Charles N. Pegram

CN

Statistics

Publications

38

Citations

2.9K

H-Index

28

Active since

1977

Affiliations

Duke Medical Center(Current)

Duke University Hospital

Duke University

Pediatric Brain Tumor Foundation

National Cancer Institute

Charles N. Pegram is an author at Duke Medical Center specializing in oncology, medicine, and brain tumors.

Publications per year

1977–2016

38

Publications

38

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Carol J. Wikstrand, Laura P. Hale, Surinder K. Batra et al. · PubMed · 1995 · 471 citations

Pharmacy, Cancer Biology, Oncology +17

Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

David A. Reardon, Gamal Akabani, R. Edward Coleman et al. · Journal of Clinical Oncology · 2005 · 200 citations

Medicine, Nuclear Medicine, Oncology +17

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Darell D. Bigner, Mark T. Brown, Allan H. Friedman et al. · Journal of Clinical Oncology · 1998 · 195 citations

Medicine, Nuclear Medicine, Oncology +14

Phase II Trial of Murine <sup>131</sup>I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

David A. Reardon, Gamal Akabani, R. Edward Coleman et al. · Journal of Clinical Oncology · 2002 · 151 citations

Medicine, Oncology, Pharmacology +17

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Ilkcan Cokgor, Gamal Akabani, Chien‐Tsun Kuan et al. · Journal of Clinical Oncology · 2000 · 138 citations

Medicine, Nuclear Medicine, Oncology +15

1–5 of 38